Breaking Finance News

A report released today by Berenberg about Synthomer (LON:SYNT) holds the target price at 505.00GBX

Only yesterday Synthomer (LON:SYNT) traded 0.09% higher at 445.80GBX. SYNT’s 50-day average is 406.98GBX and its two hundred day average is 376.67GBX. With the last close up 19.20% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the date range. Trade Volume was up over the average, with 982,076 shares of SYNT changing hands over the typical 609,010

Berenberg hold steady the target price of Synthomer (LON:SYNT) at 505.00GBX indicating a possible upside of 0.13%.

On Monday February 06, 2017, Morgan Stanley reported on Synthomer (LON:SYNT) held steady the target price at 350.00GBX that suggested a downside of -0.22%.

See Chart Below

Synthomer (LON:SYNT)

Synthomer has PE ratio of 19.52 with a one year low of 274.20GBX and a one year high of 470.20GBX and has a total market value of 0 GBX.

General Information About Synthomer (LON:SYNT)

Synthomer Plc is a United Kingdom-based specialty chemical company. The Company supplies lattices and specialty emulsion polymers for markets, including paper and board, constructions and coatings, health and protection, functional polymers, performance polymers, and carpet, compounds and foam. It operates in segments, including Europe and North America (ENA) and Asia and Rest of World (ARW). It offers various products, including synthetic binders for paper and board coating; acrylic, styrene acrylic and vinyl acetate based binders; nitrile butadiene rubber (NBR) and polychloroprene (CR) lattices for medical and examination gloves; synthetic latex or natural latex; polyvinyl alcohols under Alcotex brand; lithene products; carboxylated styrene butadiene rubber and high solid styrene butadiene rubber lattices; acrylic dispersions, and adhesive dispersions. It offers lattices and dispersions for textile floorcovering applications under the Litex T, Lipolan T and Plextol T brands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.